{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:18:49Z","timestamp":1794907129898,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"American Kratom Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>\n                      Kratom derives from\n                      <jats:italic>Mitragyna speciosa<\/jats:italic>\n                      (Korth.), a tropical tree in the genus\n                      <jats:italic>Mitragyna<\/jats:italic>\n                      (Rubiaceae) that also includes the coffee tree. Kratom leaf powders, tea-like decoctions, and commercial extracts are taken orally, primarily for health and well-being by millions of people globally. Others take kratom to eliminate opioid use for analgesia and manage opioid withdrawal and use disorder. There is debate over the possible respiratory depressant overdose risk of the primary active alkaloid, mitragynine, a partial \u03bc-opioid receptor agonist, that does not signal through \u00df-arrestin, the primary opioid respiratory depressant pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Compare the respiratory effects of oral mitragynine to oral oxycodone in rats with the study design previously published by US Food and Drug Administration (FDA) scientists for evaluating the respiratory effects of opioids (Xu et al., Toxicol Rep 7:188\u2013197, 2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood gases, observable signs, and mitragynine pharmacokinetics were assessed for 12\u00a0h after 20, 40, 80, 240, and 400\u00a0mg\/kg oral mitragynine isolate and 6.75, 60, and 150\u00a0mg\/kg oral oxycodone hydrochloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Oxycodone administration produced significant dose-related respiratory depressant effects and pronounced sedation with one death each at 60 and 150\u00a0mg\/kg. Mitragynine did not yield significant dose-related respiratory depressant or life-threatening effects. Sedative-like effects, milder than produced by oxycodone, were evident at the highest mitragynine dose. Maximum oxycodone and mitragynine plasma concentrations were dose related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consistent with mitragynine\u2019s pharmacology that includes partial \u00b5-opioid receptor agonism with little recruitment of the respiratory depressant activating \u03b2-arrestin pathway, mitragynine produced no evidence of respiratory depression at doses many times higher than known to be taken by humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-022-06244-z","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:02:37Z","timestamp":1667001757000},"page":"3793-3804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Respiratory effects of oral mitragynine and oxycodone in a rodent model"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-0041","authenticated-orcid":false,"given":"Jack E.","family":"Henningfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Rodricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Magnuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn A.","family":"Huestis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"6244_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/life12020193","volume":"12","author":"I Ahmad","year":"2022","unstructured":"Ahmad I, Prabowo WC, Arifuddin M, Fadraersada J, Indriyanti N, Herman H, Purwoko RY, Nainu F, Rahmadi A, Paramita S, Kuncoro H, Mita N, Narsa AC, Prasetya F, Ibrahim A, Rijai L, Alam G, Mun\u2019im A, Dej-adisai S, (2022) Mitragyna species as pharmacological agents: from abuse to promising pharmaceutical products. Life 12:193. https:\/\/doi.org\/10.3390\/life12020193","journal-title":"Life"},{"key":"6244_CR2","unstructured":"American Kratom Association (2019) The increase in consumer use of kratom in the United States, June 2019. https:\/\/assets.website-files.com\/61858fcec654303987617512\/619dd9d68bd48315873c4952_Kratom_Population_2019.pdf.\u00a0Accessed 19 Oct 2022"},{"issue":"4","key":"6244_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.yebeh.2012.02.011","volume":"23","author":"E Artsy","year":"2012","unstructured":"Artsy E, McCarthy DC, Hurwitz S, Pavlova MK, Dworetzky BA, Lee JW (2012) Use of modafinil in patients with epilepsy. Epilepsy Behav 23(4):405\u2013408. https:\/\/doi.org\/10.1016\/j.yebeh.2012.02.011","journal-title":"Epilepsy Behav"},{"issue":"4","key":"6244_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1055\/a-0770-3683","volume":"85","author":"BA Avery","year":"2019","unstructured":"Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ (2019) McCurdy CR (2019) Comparative pharmacokinetics of mitragynine after oral administration of Mitragyna speciosa (Kratom) leaf extracts in rats. Planta Med 85(4):340\u2013346. https:\/\/doi.org\/10.1055\/a-0770-3683","journal-title":"Planta Med"},{"key":"6244_CR5","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s11064-018-2623-7","volume":"43","author":"E Bahramnjead","year":"2018","unstructured":"Bahramnjead E, Kazemi Roodsari S, Rahimi N, Etemadi P, Aghaei I, Dehpour AR (2018) Effects of modafinil on clonic seizure threshold induced by pentylenetetrazole in mice: involvement of glutamate, nitric oxide, GABA, and serotonin pathways. Neurochem Res 43:2025\u20132037. https:\/\/doi.org\/10.1007\/s11064-018-2623-7","journal-title":"Neurochem Res"},{"key":"6244_CR6","doi-asserted-by":"publisher","first-page":"108235","DOI":"10.1016\/j.drugalcdep.2020.108235","volume":"215","author":"A Behnood-Rod","year":"2020","unstructured":"Behnood-Rod A, Chellian R, Wilson R, Hiranita T, Sharma A, Leon F, McCurdy CR, McMahon LR, Bruijnzeel AW (2020) Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug Alcohol Depend 215:108235. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108235","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"6244_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1360-0443.2008.02209.x","volume":"103","author":"EW Boyer","year":"2008","unstructured":"Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH (2008) Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 103(6):1048\u20131050. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02209.x","journal-title":"Addiction"},{"key":"6244_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jep.2017.03.020","volume":"202","author":"PN Brown","year":"2017","unstructured":"Brown PN, Lund JA, Murch SJ (2017) A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom. J Ethnopharmacol 202:302\u2013325. https:\/\/doi.org\/10.1016\/j.jep.2017.03.020","journal-title":"J Ethnopharmacol"},{"key":"6244_CR9","unstructured":"Centers for Disease Control and Prevention (CDC), National Center for Health statistics (2021) Drug Overdose Deaths in the U.S. Top 100,000 Annually. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm. Accessed 8 March 2022"},{"issue":"18","key":"6244_CR10","doi-asserted-by":"publisher","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","volume":"64","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, DiBerto JF, Faouzi A, Bernhard SM, Guttridge AM Ramsey, S, et al (2021) A novel mitragynine analog with low efficacy mu opioid receptor agonism displays antinociception with attenuated adverse effects. J Med Chem 64(18):13873\u201313892","journal-title":"J Med Chem"},{"key":"6244_CR11","doi-asserted-by":"publisher","first-page":"968786","DOI":"10.1155\/2015\/968786","volume":"2015","author":"E Cinosi","year":"2015","unstructured":"Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li JH, Yu WJ, Kapit\u00e1ny-F\u00f6v\u00e9ny M, Farkas J, Di Giannantonio M, Corazza O (2015) Following \u201cthe roots\u201d of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. Biomed Res Int 2015:968786. https:\/\/doi.org\/10.1155\/2015\/968786","journal-title":"Biomed Res Int"},{"key":"6244_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","volume":"202","author":"MA Coe","year":"2019","unstructured":"Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE (2019) Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend 202:24\u201332. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.05.005","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"6244_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/10550887.2020.1788914","volume":"38","author":"JR Covvey","year":"2020","unstructured":"Covvey JR, Vogel SM, Peckham AM, Evoy KE (2020) Prevalence and characteristics of selfreported kratom use in a representative US general population sample. J Addict Dis 38(4):506\u2013513","journal-title":"J Addict Dis"},{"issue":"24","key":"6244_CR14","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.jchromb.2009.06.023","volume":"877","author":"NV de Moraes","year":"2009","unstructured":"de Moraes NV, Moretti RA, Furr EB III, McCurdy CR, Lanchote VL (2009) Determination of mitragynine in rat plasma by LC\u2013MS\/MS: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 877(24):2593\u20132597. https:\/\/doi.org\/10.1016\/j.jchromb.2009.06.023","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"6244_CR15","unstructured":"Epilepsy Foundation (2020) Triggers of seizures: over-the-counter medications. https:\/\/www.epilepsy.com\/learn\/triggers-seizures\/over-counter-medications. Accessed 8 March 2022"},{"key":"6244_CR16","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2015) Kratom drug profile. https:\/\/www.emcdda.europa.eu\/publications\/drug-profiles\/kratom_en. Accessed 7 March 2022"},{"key":"6244_CR17","unstructured":"Figura C, Barrett M, Atkinson TJ (2020) A kratom primer: miracle medicine or herb of abuse? Pract Pain Manag 20(5). https:\/\/www.practicalpainmanagement.com\/treatments\/pharmacological\/non-opioids\/kratom-primer-miracle-medicine-herb-abuse. Accessed 8 March 2022"},{"key":"6244_CR18","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.drugalcdep.2020.107849","volume":"208","author":"A Garcia-Romeu","year":"2020","unstructured":"Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR (2020) Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend 208:107849. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107849","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"6244_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMc1811055","volume":"380","author":"K Gershman","year":"2019","unstructured":"Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R, Monte AA (2019) Deaths in Colorado attributed to kratom. N Engl J Med 380(1):97\u201398. https:\/\/doi.org\/10.1056\/NEJMc1811055","journal-title":"N Engl J Med"},{"key":"6244_CR20","unstructured":"Giroir BP (2018) Letter from the Assistant Secretary of Health to the Administrator of the Drug Enforcement Administration to Rescind Previous Support to Permanently Place Mitragynine and 7-hydroxymitragynine in Schedule I of the Controlled Substances Act 2018. https:\/\/static1.squarespace.com\/static\/54d50ceee4b05797b34869cf\/t\/60145eab6df59e7e36a7cfc1\/1611947693695\/dhillon-8.16.2018-response-letter-from-ash-radm-giroir.pdf. Accessed 8 March 2022"},{"key":"6244_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","volume":"176","author":"O Grundmann","year":"2017","unstructured":"Grundmann O (2017) Patterns of Kratom use and health impact in the US\u2014results from an online survey. Drug Alcohol Depend 176:63\u201370. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.03.007","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"6244_CR22","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/add.14371","volume":"113","author":"O Grundmann","year":"2018","unstructured":"Grundmann O, Brown PN, Henningfield J, Swogger M, Walsh Z (2018) The therapeutic potential of kratom. Addiction 113(10):1951\u20131953. https:\/\/doi.org\/10.1111\/add.14371","journal-title":"Addiction"},{"issue":"7","key":"6244_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/bph.14913","volume":"177","author":"AM Gutridge","year":"2020","unstructured":"Gutridge AM, Robins MT, Cassell RJ, Uprety R, Mores KL, Ko MJ, Pasternak GW, Majumdar S, van Rijn RM (2020) G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder. Br J Pharmacol 177(7):1497\u20131513. https:\/\/doi.org\/10.1111\/bph.14913","journal-title":"Br J Pharmacol"},{"key":"6244_CR24","doi-asserted-by":"publisher","first-page":"136500","DOI":"10.1016\/j.neulet.2022.136500","volume":"773","author":"N Harun","year":"2022","unstructured":"Harun N, Kamaruzaman NA, Mohamed Sofian Z, Hassan Z (2022) Mini review: potential therapeutic values of mitragynine as an opioid substitution therapy. Neurosci Lett 773:136500. https:\/\/doi.org\/10.1016\/j.neulet.2022.136500","journal-title":"Neurosci Lett"},{"key":"6244_CR25","doi-asserted-by":"publisher","first-page":"708019","DOI":"10.3389\/fphar.2021.708019","volume":"12","author":"R Hassan","year":"2021","unstructured":"Hassan R, Sreenivasan S, M\u00fcller CP, Hassan Z (2021) Methadone, buprenorphine, and clonidine attenuate mitragynine withdrawal in rats. Front Pharmacol 12:708019. https:\/\/doi.org\/10.3389\/fphar.2021.708019","journal-title":"Front Pharmacol"},{"issue":"5","key":"6244_CR26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/adb.12639","volume":"24","author":"SE Hemby","year":"2019","unstructured":"Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR (2019) Abuse liability and therapeutic potential of the Mitragyna speciosa (Kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol 24(5):874\u2013885. https:\/\/doi.org\/10.1111\/adb.12639","journal-title":"Addict Biol"},{"issue":"2","key":"6244_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","volume":"235","author":"JE Henningfield","year":"2018","unstructured":"Henningfield JE, Fant RV, Wang DW (2018) The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology 235(2):573\u2013589. https:\/\/doi.org\/10.1007\/s00213-017-4813-4","journal-title":"Psychopharmacology"},{"key":"6244_CR28","doi-asserted-by":"publisher","first-page":"105851","DOI":"10.1016\/j.ypmed.2019.105851","volume":"128","author":"JE Henningfield","year":"2019","unstructured":"Henningfield JE, Grundmann O, Babin JK, Fant RV, Wang DW, Cone EJ (2019) Risk of death associated with kratom use compared to opioids. Prev Med 128:105851. https:\/\/doi.org\/10.1016\/j.ypmed.2019.105851","journal-title":"Prev Med"},{"key":"6244_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.amepre.2021.07.022","volume":"62","author":"JE Henningfield","year":"2021","unstructured":"Henningfield JE, Grundmann O, Garcia-Romeu A, Swogger MT (2021) We need better estimates of kratom use prevalence. Am J Prev Med 62:132\u2013133. https:\/\/doi.org\/10.1016\/j.amepre.2021.07.022","journal-title":"Am J Prev Med"},{"key":"6244_CR30","doi-asserted-by":"publisher","first-page":"775073","DOI":"10.3389\/fphar.2021.775073","volume":"12","author":"JE Henningfield","year":"2022","unstructured":"Henningfield JE, Wang DW, Huestis MA (2022) Kratom abuse potential 2021: an updated eight factor analysis. Front Pharmacol 12:775073. https:\/\/doi.org\/10.3389\/fphar.2021.775073","journal-title":"Front Pharmacol"},{"issue":"14","key":"6244_CR31","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1111\/bph.15832","volume":"179","author":"R Hill","year":"2022","unstructured":"Hill R, Kruegel AC, Javitch JA, Lane JR, Canals M (2022) The respiratory depressant effects ofmitragynine are limited by its conversion to 7-OH mitragynine. Br J Pharmacol 179(14):3875\u20133885. https:\/\/doi.org\/10.1111\/bph.15832","journal-title":"Br J Pharmacol"},{"issue":"3","key":"6244_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.drugalcdep.2012.11.014","volume":"131","author":"MA Huestis","year":"2013","unstructured":"Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL (2013) Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depend 131(3):258\u2013262. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.11.014","journal-title":"Drug Alcohol Depend"},{"key":"6244_CR33","doi-asserted-by":"publisher","unstructured":"Jagabalan Y, Zainal H, Al Ganaby A, Murugaiyah V, Ramanathan S (2019) Pharmacokinetic modeling of single dose Kratom (mitragynine) in rats.\u00a0Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018, Putrajaya, Malaysia. Front Pharmacol. https:\/\/doi.org\/10.3389\/conf.fphar.2018.63.00087","DOI":"10.3389\/conf.fphar.2018.63.00087"},{"issue":"4","key":"6244_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/acs.jnatprod.0c01163","volume":"84","author":"SH Kamble","year":"2021","unstructured":"Kamble SH, Berthold EC, King TI, Raju Kanumuri SR, Popa R, Herting JR, Le\u00f3n F, Sharma A, McMahon LR, Avery BA, McCurdy CR (2021) Pharmacokinetics of eleven kratom alkaloids following an oral dose of either traditional or commercial kratom products in rats. J Nat Prod 84(4):1104\u20131112. https:\/\/doi.org\/10.1021\/acs.jnatprod.0c01163","journal-title":"J Nat Prod"},{"issue":"21","key":"6244_CR35","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1021\/jacs.6b00360","volume":"138","author":"AC Kruegel","year":"2016","unstructured":"Kruegel AC, Gassaway MM, Kapoor A, V\u00e1radi A, Majumdar S, Filizola M, Javitch JA, Sames D (2016) Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc 138(21):6754\u20136764. https:\/\/doi.org\/10.1021\/jacs.6b00360","journal-title":"J Am Chem Soc"},{"issue":"6","key":"6244_CR36","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","volume":"5","author":"AC Kruegel","year":"2019","unstructured":"Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, Javitch JA, Majumdar S, Sames D (2019) 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Cent Sci 5(6):992\u20131001. https:\/\/doi.org\/10.1021\/acscentsci.9b00141","journal-title":"ACS Cent Sci"},{"issue":"1","key":"6244_CR37","first-page":"145","volume":"198","author":"E Macko","year":"1972","unstructured":"Macko E, Weisbach JA, Douglas B (1972) Some observations on the pharmacology of mitragynine. Arch Int Pharmacodyn Ther 198(1):145","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"17","key":"6244_CR38","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1055\/a-1212-5475","volume":"86","author":"EA Maxwell","year":"2020","unstructured":"Maxwell EA, King TI, Kamble SH, Raju KS, Berthold EC, Le\u00f3n F, Avery BA, McMahon LR, McCurdy CR, Sharma A (2020) Pharmacokinetics and safety of mitragynine in beagle dogs. Planta Med 86(17):1278\u20131285. https:\/\/doi.org\/10.1055\/a-1212-5475","journal-title":"Planta Med"},{"key":"6244_CR39","unstructured":"McCurdy C, Grundmann O, McLaughlin J (2020) Kratom Resources. Department of Pharmacodynamics, College of Pharmacy, University of Florida. https:\/\/pd.pharmacy.ufl.edu\/research\/kratom\/. Accessed 8 March 2022"},{"issue":"2","key":"6244_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"key":"6244_CR41","doi-asserted-by":"publisher","unstructured":"National Academy of Sciences (2011) Guide for the Care and Use of Laboratory Animals: Eighth Edition, 2011. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/12910.","DOI":"10.17226\/12910"},{"key":"6244_CR42","unstructured":"National Institute on Drug Abuse (2020). Kratom Drug Facts. National Institutes of Health, Bethesda, MD. https:\/\/www.drugabuse.gov\/publications\/drugfacts\/kratom. Accessed 8 March 2022"},{"issue":"3","key":"6244_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1124\/jpet.120.000189","volume":"376","author":"S Obeng","year":"2021","unstructured":"Obeng S, Wilkerson JL, Le\u00f3n F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, Patel A, Pennington AE, Taylor VA, Ho NP, Braun T, Fortner JD, Crowley ML, Williamson MR, Pallares VLC, Mottinelli M, Lopera-Londo\u00f1o C, McCurdy CR, McMahon LR, Hiranita T (2021) Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for \u03bc-opioid receptor and opioid-like behavioral effects in rats. J Pharmacol Exp Ther 376(3):410\u2013427. https:\/\/doi.org\/10.1124\/jpet.120.000189","journal-title":"J Pharmacol Exp Ther"},{"key":"6244_CR44","unstructured":"O'Brien CP (2015). Drug addiction. In: Brunton LL, Chabner BA, Knollmann BC. eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. McGraw Hill. https:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=1613&sectionid=102159667"},{"key":"6244_CR45","doi-asserted-by":"publisher","unstructured":"Olsen EO, O\u2019Donnell J, Mattson CL, Schier JG, Wilson N (2019) Notes from the field: unintentional drug overdose deaths with kratom detected\u201427 states, July 2016\u2013December 2017. MMWR Morb Mortal Wkly Rep 68(14):326\u2013327 https:\/\/doi.org\/10.15585\/mmwr.mm6814a2","DOI":"10.15585\/mmwr.mm6814a2"},{"key":"6244_CR46","doi-asserted-by":"publisher","unstructured":"Palamar JJ (2021) Past-Year kratom use in the U.S.: Estimates from a nationally representative sample. Am J Prev Med 61(2):240-245. https:\/\/doi.org\/10.1016\/j.amepre.2021.02.004","DOI":"10.1016\/j.amepre.2021.02.004"},{"key":"6244_CR47","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.2147\/JPR.S231948","volume":"12","author":"JV Pergolizzi Jr","year":"2019","unstructured":"Pergolizzi JV Jr, Raffa RB (2019) Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res 12:3299\u20133317. https:\/\/doi.org\/10.2147\/JPR.S231948","journal-title":"J Pain Res"},{"issue":"2","key":"6244_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.aat.2015.06.001","volume":"53","author":"JV Pergolizzi Jr","year":"2015","unstructured":"Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE (2015) The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan 53(2):71\u201376. https:\/\/doi.org\/10.1016\/j.aat.2015.06.001","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"6244_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.drugpo.2019.05.003","volume":"70","author":"WC Prozialeck","year":"2019","unstructured":"Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D (2019) Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy 70:70\u201377. https:\/\/doi.org\/10.1016\/j.drugpo.2019.05.003","journal-title":"Int J Drug Policy"},{"issue":"15","key":"6244_CR50","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.3390\/ijerph17155512","volume":"17","author":"WC Prozialeck","year":"2020","unstructured":"Prozialeck WC, Edwards JR, Lamar PC, Plotkin BJ, Sigar IM, Grundmann O, Veltri CA (2020) Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago. Int J Environ Res Public Health 17(15):5512. https:\/\/doi.org\/10.3390\/ijerph17155512","journal-title":"Int J Environ Res Public Health"},{"key":"6244_CR51","doi-asserted-by":"publisher","first-page":"729220","DOI":"10.3389\/fphar.2021.729220","volume":"12","author":"WC Prozialeck","year":"2021","unstructured":"Prozialeck WC, Lamar PC, Krupp M 2nd, Moon M, Phelps LE, Grundmann O (2021) Kratom use within the context of the evolving opioid crisis and the COVID-19 pandemic in the United States. Front Pharmacol 12:729220. https:\/\/doi.org\/10.3389\/fphar.2021.729220","journal-title":"Front Pharmacol"},{"issue":"4","key":"6244_CR52","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YCO.0000000000000621","volume":"33","author":"S Ramanathan","year":"2020","unstructured":"Ramanathan S, McCurdy CR (2020) Kratom (Mitragyna speciosa): worldwide issues. Curr Opin Psychiatry 33(4):312\u2013318. https:\/\/doi.org\/10.1097\/YCO.0000000000000621","journal-title":"Curr Opin Psychiatry"},{"issue":"S1","key":"6244_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.05233","volume":"34","author":"ME Reeve","year":"2020","unstructured":"Reeve ME, Obeng S, Oyola FL, Behnke M, Restrepo LF, Patel A, Ho NP, Williamson MR, Jimenez LR, McCurdy CR, McMahon LR (2020) The adrenergic a2 receptor-mediated discriminative-stimulus effects of mitragynine, the primary alkaloid in Kratom (Mitragyna speciosa) in rats. FASEB J 34(S1):1. https:\/\/doi.org\/10.1096\/fasebj.2020.34.s1.05233","journal-title":"FASEB J"},{"issue":"1","key":"6244_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/add.15082","volume":"116","author":"J Schimmel","year":"2021","unstructured":"Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL (2021) Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addiction 116(1):176\u2013181. https:\/\/doi.org\/10.1111\/add.15082","journal-title":"Addiction"},{"issue":"3","key":"6244_CR55","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","volume":"132","author":"Z Schuman-Olivier","year":"2013","unstructured":"Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ (2013) Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend 132(3):580\u2013586. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.04.006","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"6244_CR56","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/dta.2604","volume":"11","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kamble SH, Le\u00f3n F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, Avery BA (2019) Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandemmass spectrometry. Drug Test Anal 11(8):1162\u20131171. https:\/\/doi.org\/10.1002\/dta.2604","journal-title":"Drug Test Anal"},{"issue":"3","key":"6244_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17425255.2021.1853706","volume":"17","author":"A Sharma","year":"2021","unstructured":"Sharma A, McCurdy CR (2021) Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder. Expert Opin Drug Metab Toxicol 17(3):255\u2013257. https:\/\/doi.org\/10.1080\/17425255.2021.1853706","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Pt 1","key":"6244_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainresbull.2016.05.004","volume":"126","author":"D Singh","year":"2016","unstructured":"Singh D, Narayanan S, Vicknasingam B (2016) Traditional and non-traditional uses of Mitragynine (Kratom): a survey of the literature. Brain Res Bull 126(Pt 1):41\u201346. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.05.004","journal-title":"Brain Res Bull"},{"key":"6244_CR59","doi-asserted-by":"publisher","first-page":"135632","DOI":"10.1016\/j.neulet.2021.135632","volume":"745","author":"FW Suhaimi","year":"2021","unstructured":"Suhaimi FW, Hassan Z, Mansor SM, M\u00fcller CP (2021) The effects of chronic mitragynine (Kratom) exposure on the EEG in rats. Neurosci Lett 745:135632. https:\/\/doi.org\/10.1016\/j.neulet.2021.135632","journal-title":"Neurosci Lett"},{"key":"6244_CR60","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.drugalcdep.2017.10.012","volume":"183","author":"MT Swogger","year":"2018","unstructured":"Swogger MT, Walsh Z (2018) Kratom use and mental health: a systematic review. Drug Alcohol Depend 183:134\u2013140. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.10.012","journal-title":"Drug Alcohol Depend"},{"key":"6244_CR61","doi-asserted-by":"publisher","first-page":"801855","DOI":"10.3389\/fphar.2022.801855","volume":"13","author":"MT Swogger","year":"2022","unstructured":"Swogger MT, Smith KE, Garcia-Romeu A, Grundmann O, Veltri CA, Henningfield J, Busch LY (2022) Understanding kratom use: a guide for healthcare providers. Front Pharmacol 13:801855. https:\/\/doi.org\/10.3389\/fphar.2022.801855","journal-title":"Front Pharmacol"},{"issue":"1","key":"6244_CR62","doi-asserted-by":"publisher","first-page":"19158","DOI":"10.1038\/s41598-020-76119-w","volume":"10","author":"DA Todd","year":"2020","unstructured":"Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-Bocanegra L, Tanna RS, McIntosh S, Raja HA, Graf TN, Hemby SE, Paine MF (2020) Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions. Sci Rep 10(1):19158. https:\/\/doi.org\/10.1038\/s41598-020-76119-w","journal-title":"Sci Rep"},{"key":"6244_CR63","unstructured":"U.S. Department of Health and Human Services (2021) Overdose Prevention Strategy. https:\/\/www.hhs.gov\/overdose-prevention\/. Accessed 8 March 2022"},{"key":"6244_CR64","unstructured":"U.S. Drug Enforcement Administration (DEA) (2016) DEA Rulemaking Docket, Comment on FR Doc # 2016\u201324659, Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine into Schedule I. Public comments on FR Doc # 2016\u201324659 (23,220 public comments). https:\/\/www.regulations.gov\/docket\/DEA-2016-0015\/comments. Accessed 8 March 2022"},{"issue":"5","key":"6244_CR65","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","volume":"24","author":"A Umbricht","year":"2004","unstructured":"Umbricht A, Huestis MA, Cone EJ, Preston KL (2004) Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 24(5):479\u2013487. https:\/\/doi.org\/10.1097\/01.jcp.0000138766.15858.c6","journal-title":"J Clin Psychopharmacol"},{"key":"6244_CR66","unstructured":"Underwood W, Anthony R (2020) AVMA guidelines for the euthanasia of animals: 2020 edition. American Veterinary Medical Association. https:\/\/www.spandidos-publications.com\/var\/AVMA_euthanasia_guidelines_2020.pdf. Accessed 9 March 2022"},{"key":"6244_CR67","unstructured":"United Nations Commission on Narcotic Drugs (2021) Implementation of the international drug control treaties: changes in the scope of control of substances Summary of assessments, findings and recommendations of the 44th World Health Organization\u2019s (WHO) Expert Committee on Drug Dependence (ECDD), 11\u201315 October 2021: Kratom, mitragynine, 7-hydroxymitragynine. https:\/\/www.unodc.org\/documents\/commissions\/CND\/CND_Sessions\/CND_64Reconvened\/ECN72021_CRP12_V2108992.pdf. Accessed 10 March 2022"},{"issue":"18","key":"6244_CR68","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","volume":"59","author":"A V\u00e1radi","year":"2016","unstructured":"V\u00e1radi A, Marrone GF, Palmer TC, Narayan A, Szab\u00f3 MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, Hunkele A, Pagirsky J, Eans SO, Medina JM, Xu J, Pan YX, Borics A, Pasternak GW, McLaughlin JP, Majumdar S (2016) Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2. J Med Chem 59(18):8381\u20138397. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00748","journal-title":"J Med Chem"},{"key":"6244_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/SAR.S164261","volume":"10","author":"C Veltri","year":"2019","unstructured":"Veltri C, Grundmann O (2019) Current perspectives on the impact of Kratom use. Subst Abuse Rehabil 10:23\u201331. https:\/\/doi.org\/10.2147\/SAR.S164261","journal-title":"Subst Abuse Rehabil"},{"issue":"4","key":"6244_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drugpo.2009.12.003","volume":"21","author":"B Vicknasingam","year":"2010","unstructured":"Vicknasingam B, Narayanan S, Beng GT, Mansor SM (2010) The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 21(4):283\u2013288. https:\/\/doi.org\/10.1016\/j.drugpo.2009.12.003","journal-title":"Int J Drug Policy"},{"key":"6244_CR71","doi-asserted-by":"publisher","first-page":"108310","DOI":"10.1016\/j.drugalcdep.2020.108310","volume":"216","author":"LL Wilson","year":"2020","unstructured":"Wilson LL, Harris HM, Eans SO, Brice-Tutt AC, Cirino TJ, Stacy HM, Simons CA, Le\u00f3n F, Sharma A, Boyer EW, Avery BA (2020) Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug Alcohol Depend 216:108310. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108310","journal-title":"Drug Alcohol Depend"},{"key":"6244_CR72","unstructured":"World Health Organization, Expert Committee on Drug Dependence (WHO ECDD) (2021) Pre-review report: kratom (Mitragyna speciosa), mitragynine, and 7-hydroxymitraginine for the forty-fourth meeting of the ECDD, Geneva, 11\u201315 October 2021. https:\/\/www.who.int\/publications\/m\/item\/kratom-mitragynine-7-hydroxymitragynine-critical-review-report. Accessed 8 March 2022"},{"key":"6244_CR73","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.toxrep.2020.01.008","volume":"7","author":"L Xu","year":"2020","unstructured":"Xu L, Chockalingam A, Stewart S, Shea K, Matta MK, Narayanasamy S, Pilli NR, Volpe DA, Weaver J, Zhu H, Davis MC, Rouse R (2020) Developing an animal model to detect drug-drug interactions impacting drug-induced respiratory depression. Toxicol Rep 7:188\u2013197. https:\/\/doi.org\/10.1016\/j.toxrep.2020.01.008","journal-title":"Toxicol Rep"},{"issue":"6","key":"6244_CR74","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/cts.13080","volume":"14","author":"L Xu","year":"2021","unstructured":"Xu L, Krishna A, Stewart S, Shea K, Racz R, Weaver JL, Volpe DA, Pilli NR, Narayanasamy S, Florian J, Patel V, Matta MK, Stone MB, Zhu H, Davis MC, Strauss DG, Rouse R (2021) Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat. Clin Transl Sci 14(6):2208\u20132219. https:\/\/doi.org\/10.1111\/cts.13080","journal-title":"Clin Transl Sci"},{"issue":"10","key":"6244_CR75","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s00213-018-4974-9","volume":"235","author":"K Yue","year":"2018","unstructured":"Yue K, Kopajtic TA, Katz JL (2018) Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology 235(10):2823\u20132829. https:\/\/doi.org\/10.1007\/s00213-018-4974-9","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06244-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06244-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06244-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:09:30Z","timestamp":1668643770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06244-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6244"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06244-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jack E. Henningfield is an employee of PinneyAssociates which provides scientific and regulatory consulting to the American Kratom Association (AKA) and its affiliated American Kratom Foundation (AKF), as well as to the developers of potential kratom-based dietary supplements and medicines. Marilyn A. Huestis consults with PinneyAssociates, including the AKA and AKF, as well as to the developers of potential kratom-based dietary supplements and medicines. Aaron Magnuson is an employee of Mountain West Research, LLC (formerly CARE Research, LLC) which was awarded the contract to conduct the study following a competitive bidding process. Joseph V Rodricks, PhD, is a consulting toxicologist currently employed by Ramboll Health and Environment providing global consulting services evaluating the safety and toxicology of dietary ingredients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}